5d 1m 3m 1y 5y 10y
There are no Transcripts on CORX.
CORX vs. ETF Alternatives
Tue, Jul. 1, 11:09 AM
- Cortex Pharmaceuticals (CORX +8.5%) enters into a license agreement with the University of Illinois for the exclusive rights to patents covering the use of cannabinoids for the treatment of sleep-related breathing disorders. The company is currently developing the cannabinoid dronabinol (D9-tetrahydrocannabinol) for the treatment of obstructive sleep apnea (OSA).
- Dronabinol is an FDA-approved generic drug indicated for AIDS-related anorexia and chemotherapy-induced emesis. The sleep apnea indication is an expansion of its label that will require the submission of a supplemental new drug application (sNDA).
Other TSLA news & PR
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.